Vertex Pharmaceuticals (VRTX): Rep. Lisa C. McClain (MI09) disclosed a purchase $1K–$15K
Rep. Lisa C. McClain (MI09) disclosed a purchase of Vertex Pharmaceuticals in the $1K–$15K range.
- $1,001–$15,000
- Reported range · official band, not an exact amount
- 245 days
- Disclosure lag
- Traded
- Dec 11, 2024
- Disclosed
- Aug 13, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 8, 2024InsiderCEO sold ~$7.83M of VRTX shares in the open market
- Nov 11, 2024InsiderCFO sold ~$1.55M of VRTX shares in the open market
- Nov 15, 2024InsiderOfficer sold ~$7.2K of VRTX shares in the open market
What came next
- Dec 13, 2024FDAFDA drug approval: Orkambi
- Dec 13, 2024FDAFDA drug approval: Orkambi
- Dec 20, 2024FDAFDA drug approval: Alyftrek
- Dec 20, 2024FDAFDA drug approval: Trikafta (Copackaged)
- Dec 20, 2024FDAFDA drug approval: Trikafta (Copackaged)
- Jan 30, 2025FDAFDA drug approval: Journavx
- Feb 11, 2025Insider · 4 peopleInsiders: 4 sales (~$3.2M)
- Feb 18, 2025Insider · 3 peopleInsiders: 3 sales (~$1.2M)
- Feb 20, 2025InsiderOfficer sold ~$533K of VRTX shares in the open market
- Feb 24, 2025CongressDisclosed purchase of VRTX — reported range $15,001 - $50,000
- Feb 25, 2025Insider · 4 peopleInsiders: 4 sales (~$1.9M)
- Feb 27, 2025Insider · 3 peopleInsiders: 3 sales (~$2.1M)
- Mar 3, 2025InsiderOfficer sold ~$1.58M of VRTX shares in the open market
- Mar 4, 2025InsiderOfficer sold ~$1.97M of VRTX shares in the open market
- Mar 10, 2025Insider · 3 peopleInsiders: 3 sales (~$4.9M)
- Mar 13, 2025InsiderOfficer sold ~$1.65M of VRTX shares in the open market
How to read House Clerk periodic transaction report
The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.
Full guide: What is the STOCK Act?
What else is on file for Vertex Pharmaceuticals
For Vertex Pharmaceuticals, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VRTX page.
Other recent filings by Rep. Lisa C. McClain (MI09)
- House Clerk periodic transaction report at CACI (CACI)Oct 12, 2026
- House Clerk periodic transaction report at Caterpillar (CAT)Oct 12, 2026
- House Clerk periodic transaction report at Immunitybio (IBRX)Oct 12, 2026
- House Clerk periodic transaction report at Immunitybio (IBRX)Oct 12, 2026
- House Clerk periodic transaction report at Microsoft (MSFT)Oct 12, 2026
The full history of Rep. Lisa C. McClain (MI09) is on the profile page.
How this filing works
Explore the data
Common questions
Which member of Congress traded Vertex Pharmaceuticals (VRTX) stock, and how much?
Rep. Lisa C. McClain (MI09) disclosed a purchase of Vertex Pharmaceuticals in the $1K–$15K range. Reported range, not an exact amount, Spouse account.
When did it happen, and when was it made public?
Traded: Dec 11, 2024. Disclosed: Aug 13, 2025. That is 245 days between the two dates.
Why is the amount a range and not an exact figure?
Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.
Where does this information come from?
From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Vertex Pharmaceuticals recently?
For Vertex Pharmaceuticals, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the VRTX page.
Does this mean VRTX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Vertex Pharmaceuticals
- SEC Form 144Nov 16, 2026
- SEC Form 144Nov 16, 2026
- SEC Form 4Nov 16, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 144Nov 12, 2026
- SEC Form 4Nov 10, 2026
Everything OQRO holds on this company is on its VRTX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
